Results 81 to 88 of about 4,873 (88)

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

Lancet Oncology, The, 2012
Arturo Molina, Scott A North, Nicholas J Vogelzang   +2 more
exaly  

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

Lancet Oncology, The, 2016
Toni K Choueiri, Thomas Powles, Nizar M Tannir   +2 more
exaly  

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

Lancet, The, 2017
Krishnansu S Tewari, Ana Oaknin, Michael J Birrer   +2 more
exaly  

Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer

Journal of Clinical Oncology, 2019
Krishnansu S Tewari, Danielle M Enserro, Barbara M Norquist   +2 more
exaly  

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

Lancet Oncology, The, 2017
Véronique Diéras, Ian E Krop, Luca Gianni   +2 more
exaly  

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non–Small-Cell Lung Cancer

Journal of Clinical Oncology, 2018
Benjamin J Solomon, Dong-Wan Kim, Yi-Long Wu   +2 more
exaly  

Breast Cancer Screening: A Final Analysis?

Ca-A Cancer Journal for Clinicians, 2003
exaly  

Branching ratios and spectral functions of τ decays: Final ALEPH measurements and physics implications

Physics Reports, 2005
exaly